Protein & Cell,
Год журнала:
2018,
Номер
9(5), С. 432 - 445
Опубликована: Апрель 28, 2018
Inter-individual
heterogeneity
in
drug
response
is
a
serious
problem
that
affects
the
patient’s
wellbeing
and
poses
enormous
clinical
financial
burdens
on
societal
level.
Pharmacogenomics
has
been
at
forefront
of
research
into
impact
individual
genetic
background
variability
or
toxicity,
recently
gut
microbiome,
which
also
called
second
genome,
recognized
as
an
important
player
this
respect.
Moreover,
microbiome
very
attractive
target
for
improving
efficacy
safety
due
to
opportunities
manipulate
its
composition.
Pharmacomicrobiomics
emerging
field
investigates
interplay
variation
drugs
disposition
(absorption,
distribution,
metabolism
excretion).
In
review,
we
provide
historical
overview
examine
current
state-of-the-art
knowledge
complex
interactions
between
host
drugs.
We
argue
combining
pharmacogenomics
pharmacomicrobiomics
will
foundation
making
major
advances
personalized
medicine.
Molecular Nutrition & Food Research,
Год журнала:
2020,
Номер
64(9)
Опубликована: Март 20, 2020
Abstract
The
full
consensus
on
the
role
of
dietary
polyphenols
as
human‐health‐promoting
compounds
remains
elusive.
two‐way
interaction
between
and
gut
microbiota
(GM)
(i.e.,
modulation
GM
by
their
catabolism
GM)
is
determinant
in
polyphenols’
effects.
identification
human
metabotypes
associated
with
a
differential
microbial
metabolism
has
opened
new
research
scenarios
to
explain
inter‐individual
variability
upon
consumption.
unequivocally
identified
so
far
are
those
involved
isoflavones
(equol
and(or)
O
‐desmethylangolesin
producers
versus
non‐producers)
ellagic
acid
(urolithin
metabotypes,
including
only
urolithin‐A
(UM‐A),
urolithin‐A,
isourolithin‐A,
urolithin‐B
(UM‐B),
non‐producers
(UM‐0)).
In
addition,
metabolites
(phenolic‐derived
postbiotics)
such
equol,
urolithins,
valerolactones,
enterolactone,
enterodiol,
8‐prenylnaringenin,
among
others,
can
exert
health
knowledge
updated
position
taken
here
i)
polyphenols,
ii)
evidence
phenolic‐derived
postbiotics
health,
iii)
biomarkers
clustering
individuals
depending
(metabotyping)
effects,
iv)
catecholamines
illustrate
intersection
personalized
nutrition
precision
medicine.
Protein & Cell,
Год журнала:
2018,
Номер
9(5), С. 432 - 445
Опубликована: Апрель 28, 2018
Inter-individual
heterogeneity
in
drug
response
is
a
serious
problem
that
affects
the
patient’s
wellbeing
and
poses
enormous
clinical
financial
burdens
on
societal
level.
Pharmacogenomics
has
been
at
forefront
of
research
into
impact
individual
genetic
background
variability
or
toxicity,
recently
gut
microbiome,
which
also
called
second
genome,
recognized
as
an
important
player
this
respect.
Moreover,
microbiome
very
attractive
target
for
improving
efficacy
safety
due
to
opportunities
manipulate
its
composition.
Pharmacomicrobiomics
emerging
field
investigates
interplay
variation
drugs
disposition
(absorption,
distribution,
metabolism
excretion).
In
review,
we
provide
historical
overview
examine
current
state-of-the-art
knowledge
complex
interactions
between
host
drugs.
We
argue
combining
pharmacogenomics
pharmacomicrobiomics
will
foundation
making
major
advances
personalized
medicine.
